Various studies demonstrated that the impressive anti-cancer effects could be achieved by inhibition of RTKs such as human epidermal growth factor receptor 2 (HER2), mesenchymal epithelial transition factor (c-MET), insulin-like growth factor 1 receptor (IGF1R) and many others (47–50). This evidence concerns the gene IGF1R and cancer.